Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470853 | 0.91 | ITGA4 (0.40) | PPARAPPARGPPARDP2RY12CYP2C19 | |
| SCHEMBL3470855 | 0.91 | ITGA4 (0.40) | PPARAPPARGPPARDP2RY12CYP2C19 | |
| SCHEMBL13731787 | 0.91 | ITGA4 (0.40) | PPARAPPARGPPARDP2RY12CYP2C19 | |
| SCHEMBL28287518 | 0.90 | KLK5 (0.39) | PPARAPPARGPPARDP2RY12 | |
| SCHEMBL17929798 | 0.81 | ADAMTS4 (0.44) | PPARAPPARGPPARDCYP2C19HIF1A | |
| SCHEMBL16538739 | 0.81 | ADAMTS4 (0.44) | PPARAPPARGPPARDCYP2C19HIF1A | |
| SCHEMBL4627986 | 0.81 | NAALAD2 (0.51) | CYP2C19MMP9 | |
| SCHEMBL4627982 | 0.81 | NAALAD2 (0.51) | CYP2C19MMP9 | |
| SCHEMBL13726857 | 0.81 | NAALAD2 (0.51) | CYP2C19MMP9 | |
| SCHEMBL7157827 | 0.79 | MMP2 (0.53) | MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448545-B1 | MANUFACTURING PROCESS FOR THE PRODUCTION OF LINACLOTIDE | CHEMI SPA (IT) | 2025-08-20 | — | — | EP | disclosed |
| US-20250042948-A1 | MANUFACTURING PROCESS FOR THE PRODUCTION OF LINACLOTIDE | CHEMI SPA (IT) | 2025-02-06 | — | — | US | disclosed |
| EP-4448545-A1 | MANUFACTURING PROCESS FOR THE PRODUCTION OF LINACLOTIDE | Chemi SPA (IT) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023110781-A1 | MANUFACTURING PROCESS FOR THE PRODUCTION OF LINACLOTIDE | CHEMI SPA (IT) | 2023-06-22 | — | — | WO | disclosed |
| EP-4194464-A1 | MANUFACTURING PROCESS FOR THE PRODUCTION OF LINACLOTIDE | Chemi SPA (IT) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042948-A1 | MANUFACTURING PROCESS FOR THE PRODUCTION OF LINACLOTIDE | LPXN, PDE8A, PDE8B | PPARA 2803/4885PPARG 3376/4885PPARD 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.